Xencor, Inc Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Xencor, Inc (XNCR) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of $1.03 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2017-05-10
- Xencor, Inc net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-03-31 was $1.03M, a 413.00% increase year-over-year.
- Xencor, Inc net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-12-31 was $119.80M, a 30856.07% increase year-over-year.
- Xencor, Inc net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-09-30 was $501.00K, a 339.47% increase year-over-year.
- Xencor, Inc net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-06-30 was $473.00K, a 43.33% increase year-over-year.
- Xencor, Inc net cash provided by (used in) financing activities, continuing operations for fiscal 2016 was $120.97M, a 3.95% increase from fiscal 2015.
- Xencor, Inc net cash provided by (used in) financing activities, continuing operations for fiscal 2015 was $116.38M, a 37686.04% increase from fiscal 2014.
- Xencor, Inc net cash provided by (used in) financing activities, continuing operations for fiscal 2014 was $308.00K, a 99.63% decline from fiscal 2013.
- Xencor, Inc net cash provided by (used in) financing activities, continuing operations for fiscal 2013 was $82.39M.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $1.03M 10-Q · filed 2017-05-10 | $120.83M derived: sum of 2 quarters · filed 2017-05-10 | $121.33M derived: sum of 3 quarters · filed 2017-05-10 | $121.80M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | $119.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $120.30M derived: sum of 2 quarters · filed 2017-03-01 | $120.77M derived: sum of 3 quarters · filed 2017-03-01 | $120.97M 10-K · filed 2017-03-01 |
| 2016-09-30 | $501.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $974.00K derived: sum of 2 quarters · filed 2016-11-02 | $1.17M 10-Q · filed 2016-11-02 | $1.56M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-06-30 | $473.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $673.00K 10-Q · filed 2016-08-03 | $1.06M derived: sum of 3 quarters · filed 2017-05-10 | $1.17M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-03-31 | $200.00K 10-Q · filed 2017-05-10 | $587.00K derived: sum of 2 quarters · filed 2017-05-10 | $701.00K derived: sum of 3 quarters · filed 2017-05-10 | $1.03M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $387.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $501.00K derived: sum of 2 quarters · filed 2017-03-01 | $831.00K derived: sum of 3 quarters · filed 2017-03-01 | $116.38M 10-K · filed 2017-03-01 |
| 2015-09-30 | $114.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $444.00K derived: sum of 2 quarters · filed 2016-11-02 | $115.99M 10-Q · filed 2016-11-02 | $116.17M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $330.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $115.88M 10-Q · filed 2016-08-03 | $116.06M derived: sum of 3 quarters · filed 2017-03-01 | $116.06M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $115.55M 10-Q · filed 2016-05-02 | $115.73M derived: sum of 2 quarters · filed 2017-03-01 | $115.72M derived: sum of 3 quarters · filed 2017-03-01 | $115.86M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $177.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $175.00K derived: sum of 2 quarters · filed 2017-03-01 | $306.00K derived: sum of 3 quarters · filed 2017-03-01 | $308.00K 10-K · filed 2017-03-01 |
| 2014-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $129.00K derived: sum of 2 quarters · filed 2015-11-04 | $131.00K 10-Q · filed 2015-11-04 | $72.64M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-06-30 | $131.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $133.00K 10-Q · filed 2015-08-05 | $72.65M derived: sum of 3 quarters · filed 2016-03-08 | $75.02M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-03-31 | $2.00K 10-Q · filed 2015-05-05 | $72.52M derived: sum of 2 quarters · filed 2016-03-08 | $74.88M derived: sum of 3 quarters · filed 2016-03-08 | $82.40M derived: sum of 4 quarters · filed 2016-03-08 |
| 2013-12-31 | $72.51M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $74.88M derived: sum of 2 quarters · filed 2016-03-08 | $82.40M derived: sum of 3 quarters · filed 2016-03-08 | $82.39M 10-K · filed 2016-03-08 |
| 2013-09-30 | $2.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $9.88M derived: sum of 2 quarters · filed 2014-11-10 | $9.88M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | $7.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | $7.51M 10-Q · filed 2014-08-01 | ||
| 2013-03-31 | -$2.00K 10-Q · filed 2014-05-15 | |||
| 2012-12-31 | -$12.00K 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |